These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1127 related articles for article (PubMed ID: 19204465)
41. In vivo hydrogen-1 magnetic resonance spectroscopy study of human intracranial tumors. Luan W; Zhang J Chin Med J (Engl); 1998 Jan; 111(1):56-8. PubMed ID: 10322655 [TBL] [Abstract][Full Text] [Related]
42. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Bartella L; Morris EA; Dershaw DD; Liberman L; Thakur SB; Moskowitz C; Guido J; Huang W Radiology; 2006 Jun; 239(3):686-92. PubMed ID: 16603660 [TBL] [Abstract][Full Text] [Related]
43. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI. Su MY; Baik HM; Yu HJ; Chen JH; Mehta RS; Nalcioglu O Technol Cancer Res Treat; 2006 Aug; 5(4):401-10. PubMed ID: 16866570 [TBL] [Abstract][Full Text] [Related]
44. Clinical evaluation of choline measurement by proton MR spectroscopy in patients with malignant tumors. Lee J; Yamaguchi T; Abe A; Shizukuishi K; Uemura H; Miyagi E; Sakata K; Inoue T Radiat Med; 2004; 22(3):148-54. PubMed ID: 15287529 [TBL] [Abstract][Full Text] [Related]
45. Evaluation of breast cancer using proton MR spectroscopy: total choline peak integral and signal-to-noise ratio as prognostic indicators. Shin HJ; Baek HM; Cha JH; Kim HH AJR Am J Roentgenol; 2012 May; 198(5):W488-97. PubMed ID: 22528931 [TBL] [Abstract][Full Text] [Related]
46. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study. Kumar M; Jagannathan NR; Seenu V; Dwivedi SN; Julka PK; Rath GK J Magn Reson Imaging; 2006 Aug; 24(2):325-32. PubMed ID: 16786567 [TBL] [Abstract][Full Text] [Related]
47. Proton MR spectroscopy of the femoral head--evaluation of patients at risk for avascular necrosis. Hou CH; Shih TT; Liu CY; Li YD; Enright T J Magn Reson Imaging; 2006 Aug; 24(2):409-17. PubMed ID: 16795092 [TBL] [Abstract][Full Text] [Related]
48. In vivo 1H MR spectroscopy of thyroid carcinoma. King AD; Yeung DK; Ahuja AT; Tse GM; Chan AB; Lam SS; van Hasselt AC Eur J Radiol; 2005 Apr; 54(1):112-7. PubMed ID: 15797300 [TBL] [Abstract][Full Text] [Related]
49. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Xu M; See SJ; Ng WH; Arul E; Back MF; Yeo TT; Lim CC Neurosurgery; 2005 May; 56(5):919-26; discussion 919-26. PubMed ID: 15854239 [TBL] [Abstract][Full Text] [Related]
50. Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy. Dewhirst MW; Poulson JM; Yu D; Sanders L; Lora-Michiels M; Vujaskovic Z; Jones EL; Samulski TV; Powers BE; Brizel DM; Prosnitz LR; Charles HC Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):480-91. PubMed ID: 15667971 [TBL] [Abstract][Full Text] [Related]
51. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor. Oya N; Aoki J; Shinozaki T; Watanabe H; Takagishi K; Endo K Radiat Med; 2000; 18(3):193-8. PubMed ID: 10972550 [TBL] [Abstract][Full Text] [Related]
52. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)]. Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303 [TBL] [Abstract][Full Text] [Related]
53. Application value of 3T ¹H-magnetic resonance spectroscopy in diagnosing breast tumors. Vassiou K; Tsougos I; Kousi E; Vlychou M; Athanasiou E; Theodorou K; Arvanitis DL; Fezoulidis IV Acta Radiol; 2013 May; 54(4):380-8. PubMed ID: 23436823 [TBL] [Abstract][Full Text] [Related]
54. Proton magnetic resonance spectroscopy in neuroblastoma: current status, prospects and limitations. Lindskog M; Spenger C; Klason T; Jarvet J; Gräslund A; Johnsen JI; Ponthan F; Douglas L; Nordell B; Kogner P Cancer Lett; 2005 Oct; 228(1-2):247-55. PubMed ID: 15946794 [TBL] [Abstract][Full Text] [Related]
55. Role of in vivo proton MR spectroscopy in the evaluation of adult brain lesions: our preliminary experience. Kumar A; Kaushik S; Tripathi RP; Kaur P; Khushu S Neurol India; 2003 Dec; 51(4):474-8. PubMed ID: 14742925 [TBL] [Abstract][Full Text] [Related]
56. Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. Seierstad T; Røe K; Olsen DR Radiother Oncol; 2007 Nov; 85(2):187-94. PubMed ID: 17937968 [TBL] [Abstract][Full Text] [Related]
57. Two-dimensional MR spectroscopy of minimal hepatic encephalopathy and neuropsychological correlates in vivo. Singhal A; Nagarajan R; Hinkin CH; Kumar R; Sayre J; Elderkin-Thompson V; Huda A; Gupta RK; Han SH; Thomas MA J Magn Reson Imaging; 2010 Jul; 32(1):35-43. PubMed ID: 20578008 [TBL] [Abstract][Full Text] [Related]
58. Proton MR spectroscopy of the breast. Tozaki M Breast Cancer; 2008; 15(3):218-23. PubMed ID: 18443899 [TBL] [Abstract][Full Text] [Related]
59. Study of the features of proton MR spectroscopy ((1)H-MRS) on amyotrophic lateral sclerosis. Han J; Ma L J Magn Reson Imaging; 2010 Feb; 31(2):305-8. PubMed ID: 20099342 [TBL] [Abstract][Full Text] [Related]
60. Improved diagnostic accuracy in differentiating malignant and benign lesions using single-voxel proton MRS of the breast at 3 T MRI. Suppiah S; Rahmat K; Mohd-Shah MN; Azlan CA; Tan LK; Aziz YF; Vijayananthan A; Wui AL; Yip CH Clin Radiol; 2013 Sep; 68(9):e502-10. PubMed ID: 23706826 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]